Back to rankings

Envista Holdings Corporation (NVST)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

55

Price

$27.25

Market Cap

$4.40B

Part 1 · What the company is worth

Overview

Envista makes the products dentists and orthodontists use every day: dental implants, clear aligners and orthodontic brackets, plus the equipment and consumables — imaging systems, drills, cements, infection-control supplies — that keep a dental office running. It sells through its own sales force and a network of dealers to over 130 countries, serving both specialists who place implants and general practitioners who handle routine care. More than half its sales come from outside the United States.

How it makes money

Envista books revenue when it ships implants, aligners, equipment or consumables to dealers and dental practices; consumables and implants are recurring, replenished purchases, while imaging systems and other capital equipment are one-off, lumpier sales tied to a practice's investment cycle. Its two segments split roughly two-thirds specialty products (implants, orthodontics) to one-third equipment and consumables, and its largest single distributor, Henry Schein, alone channels about 12% of total sales to end customers.

Revenue by segment

Specialty Products & Technologies64.4%

Dental implant systems, regenerative products and orthodontic brackets, aligners and lab products for specialists and general dentists.

Equipment & Consumables35.6%

Dental imaging systems, endodontic equipment, restorative materials, cements and infection-prevention supplies used in daily practice.

Competitive moat

Scale · Narrow

Envista describes itself as running one of the largest customer-facing sales teams in the dental industry, backed by a global dealer network reaching over 130 countries. That distribution scale is hard for smaller rivals to match, but the underlying implant and equipment categories are competitive and price-sensitive, so the advantage is narrow rather than a lock on the market.

What drives demand

Moderately cyclical

Routine dental consumables track fairly steady patient visit volumes, but elective procedures like implants and big-ticket equipment purchases are more discretionary and get postponed when practices or patients tighten spending. The mix of the two makes overall demand more resilient than typical consumer discretionary goods, but not fully immune to economic cycles.

Key risks

  • Distributor dependence — A substantial portion of sales flows through a limited number of distributors, chiefly Henry Schein, with no assurance any of them will keep purchasing at current levels or that lost volume could be quickly replaced.
  • Distributor inventory swings — The company relies on predictions of distributor and customer inventory levels to plan production; when those inventories build or run down differently than expected, reported results can diverge sharply from underlying demand.
  • Acquisition and divestiture risk — Envista routinely acquires and divests businesses to fit its portfolio strategy, and warns that earn-outs, indemnification obligations, goodwill impairments and unsatisfied deal conditions could all produce unpredictable financial results.

Customer concentration

Top customers account for 12% of revenue

Henry Schein, the company's largest distributor, accounted for approximately 12% of sales in 2025 and is expected to remain the top contributor for the foreseeable future, without a master distribution agreement guaranteeing that relationship.

The case for

Buyers argue that Envista's scale in global dental distribution and its position across both the specialist implant market and everyday consumables give it a resilient, recurring revenue base that should benefit as dental procedure volumes recover outside the U.S.

The case against

Sellers fear that heavy reliance on a handful of distributors, led by Henry Schein, leaves Envista exposed to a single relationship it does not fully control, and that elective procedure volumes remain vulnerable if patients keep deferring discretionary dental work.

Segment figures from fiscal year 2025Sources: Envista Holdings Corp — Form 10-K, fiscal year 2025

Written by the editors, published on August 18, 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$2.86B

Trailing 12 months (through 7/3/2026)

Net Income

$95M

Trailing 12 months (through 7/3/2026)

Free Cash Flow

$230M

Total Equity

$3.11B

Total Liabilities

$2.57B

Current Ratio

2.43

Interest Coverage

-

Debt/EBITDA

4.78

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

Fairly Valued

Fair Value

$24.42

Current Price

$27.25

Margin of Safety

-11.6%

Fair Value Range

$15.88 - $32.97

Estimation Methods

Analyst Target:$30.57
DCF:$38.28
PE-based:$10.29
Graham Growth:$10.96
EPV:$14.11
Analyst Consensus:Buy (12B / 10H / 0S)
Last Earnings Surprise:+19.92%

Valuation Metrics

P/E Ratio

47.14

ROE

1.5%

P/B Ratio

1.43

P/FCF

17.70

Gross Margin

55.2%

ROIC

4.5%

Profitability Radar

Value Creation (Economic Moat)

ROIC

4.5%

WACC

6.9%

ROIC − WACC

-2.4 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Fundamental Analysis Criteria

Passed (17)

  • Gross Margin 55.2%
  • P/FCF 17.70
  • P/B Ratio 1.43
  • Debt/Equity ratio
  • Operating Margin 9.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 7.1%
  • Analyst Consensus 55% Buy
  • Earnings Surprise avg 15.7%
  • Earnings Quality (OCF/NI) 3.19
  • Share Dilution -2.5%
  • Net Margin Trend 3.3% vs 2.1%
  • Piotroski F-Score 7/9

Failed (9)

  • EPS shows upward trend
  • EPS CAGR -23.35%
  • Price CAGR -1.22%
  • ROIC 4.5%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • ROE 3.1%
  • PEG Ratio 7.29

Unavailable (2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

7/9

Strong financial health

score
criteria

Earnings Quality

3.19

High quality: earnings backed by cash

Share Dilution

-2.5%

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Mr. Eric D. HammesSenior VP & CFO50
Mr. Mark E. Nance J.D.Senior VP, General Counsel & Secretary56
Mr. Robert Befidi Jr.Senior VP & President of Diagnostics50
Ms. Veronica AcurioSenior VP & President of Orthodontics54
Mr. Coree ThomasVP & Chief Accounting Officer47
Mr. Andrew ChenChief Information Officer-
Mr. Jim GustafsonVice President of Investor Relations-
Paul SumilasChief Compliance Officer-
Mr. Mischa M. ReisSenior Vice President of Strategy & Corporate Development52
Mr. Suraj SatpathyChief Human Resources officer-

Audit Risk

2

Board Risk

2

Compensation Risk

4

Shareholder Rights Risk

5

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for NVST, sourced from Markets Gazette.

No recent news for NVST.